Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora Therapeutics Inc. is based in WATERTOWN, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-236.93M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.52 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -181.70% |
| Return on Assets (Trailing 12 Months) | -119.15% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.75 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.62 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.45 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.33 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 185.28M |
| Free Float | 135.37M |
| Market Capitalization | $324.25M |
| Average Volume (Last 20 Days) | 1.23M |
| Beta (Past 60 Months) | 2.73 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.94% |
| Percentage Held By Institutions (Latest 13F Reports) | 47.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |